In Ovo Vaccine May Revolutionize Coccidiosis Control
DURHAM, N.C.--The U.S. poultry industry has the potential to achieve new standards of health and efficiency with the advent of the first-ever coccidiosis vaccine delivered via in ovoadministration. The new Inovocox® vaccine from the Poultry Health Division of Pfizer Animal Health (PPH) will provide an innovative tool for the broiler industry to help control one of the global poultry industry’s most prevalent and costly diseases.
The coccidiosis challenge
Coccidiosis is an intestinal parasitic infection that is endemic to poultry production, and can cause considerable economic loss to the poultry industry in the form of lost growth and feed conversion efficiency, mortality, and medication and treatment costs. The economic impact of the disease on the world poultry industry is estimated to exceed US $3 billion annually.
Novel vaccine, state-of-the-art delivery
Pfizer Animal Health has invested greater than 10 years into the research and development of this advanced vaccine, which is delivered to the egg even before the chicks are hatched. Inovocox is administered in ovoto eighteen- or nineteen-day-old embryonated broiler chick eggs via the technologically advanced Embrex® Inovoject® System.
Traditional coccidiosis control programs depend upon a feed administered anticoccidial drug or a vaccine that may be administered via spray to the chicks. “The in ovoadministration of Inovocox helps ensure that every bird receives a uniform dose for effective protection,” says Rebecca Poston, PhD, senior manager of Pfizer Animal Health Veterinary Medicine Research & Development (VMRD). “This breakthrough technology is based on more than a decade of research, involving millions of birds, to evaluate Inovocox for efficacy and safety.”
Inovocox vaccine contains highly immunogenic, anticoccidial-sensitive, sporulated oocysts of E. acervulina, E. tenella, and two strains of E. maxima. The strains originated from field isolates, which were screened and selected for their ability to help protect against challenge when administered in ovo,and for their sensitivity to anticoccidial drugs. Pfizer Animal Health researchers deemed it advantageous to include two strains of E. maxima, because of the more common field variation of this species which may help enhance the vaccine’s total protection package against the strains commonly found on poultry farms.
Pre-hatch exposure to coccidial organisms will allow birds to develop early immunity to the disease. Early and uniform flock immunity to coccidiosis helps provide control of clinical and subclinical coccidiosis and may result in more uniform growth and development of the flock throughout the grow-out.
Extensive safety studies show that Inovocox has no significant effect on hatch rate. Performance trials show Inovocox-vaccinated flocks will help provide attractive weight gain, feed conversion and settlement costs. In addition, Inovocox vaccine may be used as a year-round coccidiosis control program, or as part of an annual rotation program.
“One dose of Inovocox helps provide broiler birds with lifelong immunity against coccidiosis,” notes David Kelly, marketing manager, PPH. “This novel vaccine leverages the highly innovative Embrex Inovoject System, which already is utilized by more than 85 percent of the U.S. broiler industry. Inovocox helps provide the most convenient, efficient and precise method of coccidiosis protection possible.”
The Poultry Health Division of Pfizer Animal Health is a leading provider of innovative, high-performance poultry health solutions to the global poultry industry. Built upon the combined strength and experience of Embrex and Pfizer Animal Heath, the Pfizer Poultry Health is committed to developing and marketing commercially novel vaccines, mechanical and data management products which continue to provide increasing value to the global poultry health industry. For more information about the Pfizer Poultry Health, visit us online at www.pfizerpoultryhealth.com.